Get Live Data

The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Immupharma Share Price
  4. Immupharma Share Regulatory News
  5. Annual Financial Report & Notice of AGM

Pin to quick picksImmupharma Regulatory News (IMM)

Immupharma Information

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.205
Bid: 2.11
Ask: 2.27
Change: 0.00 (0.00%)
Spread: 0.16 (7.583%)
Open: 2.205
High: 0.00
Low: 0.00
Prev. Close: 2.205
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report & Notice of AGM

4 May 2016 07:01

RNS Number : 1388X
Immupharma PLC
04 May 2016
 

 

 4 MAY 2016

 

 

 

ANNUAL REPORT AND ACCOUNTS

NOTICE OF ANNUAL GENERAL MEETING: 26 MAY 2016

 

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company confirms that the Annual Report and Accounts for the year ended 31 December 2015 has been posted to shareholders.

The Annual Report will be available later today, in electronic form, for download on the Company's website www.immupharma.org.

The Company's Annual General Meeting will be held on Thursday 26 May 2016 at 10:00am at the offices of Bircham Dyson Bell LLP, 50 Broadway, London, SW1H 0BL.

-Ends-

 

 

 

For further information please contact:

 

ImmuPharma plc (www.immupharma.org)

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations

Twitter: @immupharma

 

+ 44 (0) 7721 413496

 

 

 

Panmure, Gordon (UK) Limited, NOMAD & Broker

 

+44 (0) 20 7886 2500

Fred Walsh / Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACSSSLFWDFMSELI
12345678910
Date   Source Headline
7th Feb 20077:01 amRNSBoard Changes
19th Jan 20078:57 amRNSTotal Voting Rights
5th Jan 20072:27 pmRNSIssue of Equity
27th Dec 20062:53 pmRNSTotal Voting Rights
21st Dec 20067:01 amRNSIssue of Equity
30th Oct 20067:01 amRNSFurther Phase II Data
17th Oct 20067:00 amRNSPhase II Data
2nd Oct 20067:01 amRNSFDA Meeting on Lupus
26th Sep 20067:01 amRNSInterim Results
1st Aug 20067:01 amRNSPreliminary Results
5th Jul 20067:00 amRNSStart of phase II trial
12th Jun 20065:04 pmRNSAccounting reference dates
10th May 20067:00 amRNSPhase 1 Lupus results
11th Apr 20067:00 amRNSResearch Grants
15th Feb 20061:56 pmRNSResult of EGM and Placing
24th Jan 20064:30 pmRNSSch 1 Update - ImmuPharma plc
23rd Jan 20064:27 pmRNSCirc re. ImmuPharma posted
30th Nov 20051:38 pmRNSInterim Results
27th May 20051:29 pmRNSFinal Results
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.